This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Vertex Cuts Workforce Amidst Declining Hep C Drug Sales

CAMBRIDGE, Mass. (TheStreet) -- Facing up the reality of plunging demand for its hepatitis C drug Incivek, Vertex Pharmaceuticals  (VRTX) announced the firing of 15% of its global workforce to focus the company on its still-growing cystic fibrosis drug business. 

Vertex admitted Tuesday that the number of hepatitis C patients being treated with Incivek has fallen rapidly now that a next generation of more effective medicines are on the cusp of approval, most notably Gilead Sciences' GILD sofosbuvir, which should receive FDA approval in December.

Incivek sales in the third quarter totaled $86 million, well below Street consensus of $124 million. Incivek was approved in May 2011 and became one of the fastest selling new drugs of all time, with quarterly sales exceeding $400 million. But the hepatitis C drug's fall was just as rapid as doctors advised patients to hold off treatment in anticipation of new and more effective medicines. 

Vertex will now shift most of its efforts to growing its cystic fibrosis drug business, including its approved medicine Kalydeco and the clinical development of new drugs.

Kalydeco sales in the third quarter totaled $101 million, more than double from the year-ago quarter.

Vertex expects to announce results from phase III studies of Kalydeco and the still-experimental drug VX-809 in the middle of 2014. These studies are hugely important for Vertex because the Kalydeco/VX-809 combination has the potential to vastly expand the number of cystic fibrosis patients treated. 

The job cuts announced Tuesday are expected to reduce 2014 operating expenses by $150-200 million compared to anticipated 2013 operating expenses of $1.1 billion, Vertex said.

The company expects to end 2013 with $1.3 billion in cash. 

In the third quarter and on a GAAP basis, Vertex lost $128.7 million, or 54 cents per share, on total revenue of $221.7 million. That compares to a net loss of $26.5 million, or 27 cents per share, on total revenue of $336 million, in the year-ago quarter. 

Vertex updated 2013 financial guidance and now expects lower total revenue in the range of $1 billion to $1.05 billion. Current Street consensus pegs Vertex revenue at $1.17 billion for the year. 

Kalydeco sales in 2013 are now expected to reach $360 million to $365 million, in line with current consensus of $362 million.

While Vertex is downshifting away from Incivek, the company continues to develop new hepatitis C drugs. Vertex also plans to outlicense its JAK inhibitor VX-509 which is being developed as a treatment for rheumatoid arthritis.

Vertex shares were down 2% to $76 in early trading.

 

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,912.11 -70.48 -0.42%
S&P 500 1,969.95 -8.96 -0.45%
NASDAQ 4,442.6980 -2.2110 -0.05%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs